Latest Headlines
-
BigHat Biosciences Enters Into Strategic Collaboration To Leverage Machine Learning In Antibody Discovery & Design
4/24/2024
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company.
-
AI Designs New Drugs Based On Protein Structures
4/24/2024
“It’s a real breakthrough for drug discovery,” says Gisbert Schneider, Professor at ETH Zurich’s Department of Chemistry and Applied Biosciences. Together with his former doctoral student Kenneth Atz, he has developed an algorithm that uses artificial intelligence (AI) to design new active pharmaceutical ingredients.
-
Drug Targeting Clear Cell Renal Cell Carcinoma Shows Promising Approach
4/23/2024
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).
-
Xaira Therapeutics Launches To Deliver Transformative Medicines By Advancing And Harnessing AI For Drug Discovery And Development
4/23/2024
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
OncoC4 Announces FDA Clearance Of IND Application For Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 For Solid Tumors
4/23/2024
OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced that the United States Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for ONC-841, a potential first-in-class SIGLEC 10 blocking antibody for the treatment of solid tumors.
-
Tharimmune Announces Option Agreement For Key Technologies For Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
4/23/2024
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
-
Medicure Receives US FDA Fast Track Designation For MC-1 For PNPO Deficiency
4/23/2024
Medicure Inc. ("Medicure" or the "Company") a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
-
FDA Approves Immunotherapy Drug Combo For Non-Muscle Invasive Bladder Cancer After UCLA-Led Research Shows Improved Outcomes For Patients
4/23/2024
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer.
-
Takeda, Astellas And Sumitomo Mitsui Banking Announce Master Agreement To Establish Joint Venture Company For Incubation Of Early Drug Discovery Programs
4/22/2024
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company.
-
New Copper-Catalyzed C-H Activation Strategy From Scripps Research
4/19/2024
Inspired by what human liver enzymes can do, Scripps Research chemists have developed a new set of copper-catalyzed organic synthesis reactions for building and modifying pharmaceuticals and other molecules.